Kusajili – Centralise les essais cliniques mondiaux

Kvælstofforiltes smertestillende effekt ved tandbehandling af børn Måle smerte på tand, muskel og hud ved inhalation af Niontix

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Comparing Problem Solving Treatment combined with duloxetine with Problem Solving Treatment alone for patients with major depressive disorder in primary care The primary objective is assessing the depressive symptom reduction rate of mono-treatment (PST) compared to combined treatment (PST and duloxetine) in patients with major depressive disorder. In other words, testing the hypothesis that combined treatment is more effective than mono-treatment in patients with major depressive disorder.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

An investigation of the feasibility of using a topical formulation of lidocaine (SHACT) for hysteroscopy in women To obtain initial information regarding the feasibility of using SHACT as a formulation for hysteroscopy

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Determination of anti-inflammatory efficacy of topical formulations in a UV erythema test The objective of the study is the comparison of the efficacy of a generic corticosteroid formulation with the reference listed drug Psorcon® E Emollient Ointment and the comparators Volon® A Salbe ointment and Dermoxin® Salbe ointment on suppression of UV-induced erythema in subjects with healthy skin.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

A double-blind, randomised, controlled, multi-centre safety study of a refrigerator-stable formulation of VARIVAX® in healthy 12 to 15 month-old infants

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Temocillin use in Complicated Urinary Tract Infections due to ESBL producing and AmpC hyperproducing Enterobacteriaceae in United Kingdom Demonstrate efficacy and safety of temocillin in urinary tract infections due to Extended Spectrum Beta-Lactamases producing or AmpC hyperproducing Enterobacteriaceae.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Randomizovaná, multicentrická, dvojitě slepá ověřovací studie k posouzení účinku opakovaných infúzí přípravku AIN457 (10mg/kg) oproti placebu na aktivitu onemocnění měřenou MRI scany po dobu 24. týdnů u pacientů s recidivující-remitující roztroušenou sklerózou To determine the effect of AIN457 (10 mg/kg i.v.) administered week 0, 2, 4, 8, 12, 16 and 20 compared to placebo on the number of combined unique active lesions (CUAL) observed on brain MRI scans performed every 4th week from week 4 to week 24 in patients with relapsing-remitting multiple sclerosis (RRMS). CUAL is defined as: new gadolinium [Gd]-enhanced lesions on T1-weighted, or new or enlarging lesions on T2-weighted MRI scans, without double counting.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

A study evaluating the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA) To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, 10 mg, and 20 mg over 8 weeks of treatment

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Study to determine the appropriate age for a second immunization with the Meningococcal C conjugated vaccine - To assess serum MenC-PS specific IgG levels at T0 (prior to vaccination) and at 1 month (T1) and 1 year (T2) after the second MenCC vaccination and determine whether there is a difference in IgG levels between the different age groups (persistence of vaccine induced antibody levels) - To assess serum bactericidal antibody assay (SBA) levels at T0 and at 1 month (T1) and 1 year (T2) after the second MenCC vaccination and determine whether there is a difference between the different age groups in the levels and the proportion of participants that have an SBA level of ≥8 (persistence of vaccine induced protective antibody levels). - To assess avidity of serum IgG antibodies and determine whether there is a difference in avidity between the different age groups

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

CLINICAL TRIAL NO: EU820UPV01 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TRK-820 IN HEMODIALYSIS PATIENTS WITH UREMIC PRURITUS EudraCT No: 2005-003469-18 Short Title: TRK-820 UP 5µg To compare the efficacy of three times a week i.v. treatment with TRK-820 5µg versus placebo in hemodialysis patients with UP following completion of a four-week parallel-group treatment period. Previously conducted Phase III studies showed a trend towards statistically significant results on efficacy for i.v. 5µg TRK-820 three times a week over placebo in a parallel group study with four weeks treatment as well as in a cross-over study with treatment periods of two weeks each.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun